Navigation Links
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Date:1/26/2009

lasta. Combined sales of Neulasta and NEUPOGEN in the U.S. were $884 million in the fourth quarter of 2008 versus $832 million in the fourth quarter of 2007, an increase of 6 percent primarily reflecting favorable changes in wholesaler inventories and an increase in demand for Neulasta. The increase in demand was driven by an increase in average net sales price, partially offset by a decline in units sold. Combined international sales increased 3 percent to $296 million in the fourth quarter of 2008 versus $286 million for the same quarter in the prior year. This growth reflects increased demand driven by the continued conversion from NEUPOGEN to Neulasta, partially offset by the impact of changes in foreign exchange which negatively impacted fourth quarter 2008 combined international sales by approximately $11 million. Excluding the impact of foreign exchange, combined worldwide product sales and international product sales each increased 7 percent. For the full year, worldwide combined sales of Neulasta and NEUPOGEN were $4,659 million in 2008 versus $4,277 million in 2007, a 9 percent increase primarily driven by increased demand for Neulasta.

Sales of Enbrel(R) (etanercept) increased 7 percent in the fourth quarter to $913 million versus $856 million during the same period in 2007 and increased 11 percent to $3,598 million in 2008 versus $3,230 million in 2007. Sales growth for the fourth quarter and for the full year 2008 was driven by higher demand due to increases in average net sales price. ENBREL sales growth in the fourth quarter and full year 2008 were affected by share declines in the U.S. versus the prior year due to increased competitive activity. However, sales growth continued in both rheumatology and dermatology, and ENBREL continues to maintain a leading position in both segments. For the full year, ENBREL sales were also favorably impacted by wholesaler inventory build in the first quarter of 2008 to support the shift
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
2. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
3. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... 2015 Diagenode, Inc., a leading ... Bioruptor® and complete solutions for epigenetics research, recently ... alleviating the need for manual processing. The new ... ChIP of histones or transcription factors and a ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... SAN MATEO, Calif., Nov. 3 Top-line preliminary ... investigational drug,relaxin for the treatment of acute heart ... symposium at the American Heart Association,s (AHA),Scientific Sessions ... M.D., Professor of Medicine, University of California,San Francisco, ...
... CAMBRIDGE, Mass., Nov. 3 Verenium Corporation,(Nasdaq: ... next-generation cellulosic,ethanol and high-performance specialty enzymes, announced today ... on Monday, November 10,2008 after market close. In ... conference call with live webcast on Monday, November ...
... SAN FRANCISCO, Calif., Nov. 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of new oncology therapeutics for,the treatment of ... be presenting at the following upcoming conferences:, Rodman ... York Palace Hotel, New York, Wednesday, November 12, ...
Cached Biology Technology:Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 2Verenium Corporation to Announce Third Quarter 2008 Financial Results 3Sunesis to Present at Upcoming Conferences 2
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally ... for the first time a fingerprint sensor in its ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... specially synthesized boron compounds are readily accepted in biologically ... proof of concept that could lead to new drug ... chemist Shih-Yuan Liu reported in the Journal of ... boron-nitrogen compounds with electronic and structural similarities to fundamentally ...
... Scientists in Michigan are reporting the development of a powerful ... process important in aging and disease. The probe works like ... cells. It could lead to new insights into disease processes ... Their study is scheduled for the Sept. 18 issue of ...
... COLUMBUS, Ohio Scientists here are the first to demonstrate ... in the ability of diesel exhaust to induce the growth ... for solid tumors. The researchers found that in both ... mice exposed to diesel exhaust than did in mice exposed ...
Cached Biology News:Boron-based compounds trick a biomedical protein 2Diesel exhaust is linked to cancer development via new blood vessel growth 2Diesel exhaust is linked to cancer development via new blood vessel growth 3Diesel exhaust is linked to cancer development via new blood vessel growth 4
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
BD BioCoat Laminin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... 148 cm 2 Mfr Desig: ...
Biology Products: